The effect of FAD on erythrocyte glutathione reductase activity in undialyzed uremic patients and healthy subjects

dc.contributor.authorAri Z.
dc.contributor.authorUyanik B.S.
dc.contributor.authorYigitoglu M.R.
dc.contributor.authorKutlu N.
dc.contributor.authorPirim I.
dc.date.accessioned2024-07-22T08:25:59Z
dc.date.available2024-07-22T08:25:59Z
dc.date.issued1997
dc.description.abstractThe erythrocyte glutathione reductase (GSSG-R) activity with and without FAD supplementation (Act. A and Act. B, respectively) was studied in 24 undialyzed uremic patients and 25 healthy subjects. Mean erythrocyte GSSG-R activity from normal subjects was 5.39 ± 1.43 U/g Hb (the active form). After the addition of FAD to the hemolysates, this increased to 7.79 ± 1.07 U/g Hb, an increase of 1.88 ± 0.84 U/g Hb (the inactive from) (p < 0.001). In patients with FAD supplementation, erythrocyte GSSG-R activity increased from 9.26 ± 1.19 U/g Hb to 10.06 ± 1.06 U/g Hb, an increase of 0.80 ± 0.76 U/g Hb (p < 0.01). In addition, there were significant positive correlations between the enzyme activities and plasma urea level, and negative correlations between the enzyme activities and hemoglobin concentrations in patients, but not in the controls. It was concluded that further cross-sectional in vivo studies should be made to determine whether riboflavin administration may or not be useful in preventing renal anemia.
dc.identifier.issn13000144
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20692
dc.language.isoEnglish
dc.subjectflavine adenine nucleotide
dc.subjectglutathione reductase
dc.subjectriboflavin
dc.subjectadolescent
dc.subjectadult
dc.subjectarticle
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectenzyme activity
dc.subjecterythrocyte
dc.subjectfemale
dc.subjecthuman
dc.subjectmale
dc.subjecturea blood level
dc.subjecturemia
dc.titleThe effect of FAD on erythrocyte glutathione reductase activity in undialyzed uremic patients and healthy subjects
dc.typeArticle

Files